Valeant Pharmaceuticals International said early Friday that the company’s new plaque psoriasis drug Siliq will cost $3,500 a month. Siliq, an injectable drug that Valeant got the rights for from AstraZeneca , is intended for patients with moderate-to-severe iterations of the chronic skin condition, who haven’t responded to other medications. Valeant said the $3,500 price tag was “the lowest injectable biologic psoriasis treatment currently on the market” and was evaluated and approved by its Patient Access and Pricing Committee, which was created in May 2016 after a series of scandals, including one about drug pricing, rocked the company. Valeant expects to start selling and marketing Siliq starting in the second half of this year. Siliq’s label will contain a “black box warning” about risks for patients with a history of suicidal thoughts or behavior. Valeant shares, which slumped 0.5% in premarket trade on Friday, have dropped 39.7% over the last three months, compared with a 3.7% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News